You searched for "laser trabeculoplasty"

36 results found

First UK Direct Selective Laser Trabeculoplasty (DSLT) device placed at Moorfields

Following an internationally successful Randomised Controlled Trial (RCT) comparing the Direct Selective Laser Trabeculoplasty (DSLT) with standard SLT, the first ever commercial device in the UK, the ‘Eagle’, has been installed and is in use at Moorfields Eye Hospital in London.

Predictors of IOP reduction after SLT

The aim of this study was to identify predictors of intraocular pressure reduction following selective laser trabeculoplasty (SLT) in patients with primary open-angle glaucoma, who are already taking maximally tolerated IOP-lowering medication and need further IOP reduction. In this prospective...

SLT short-term results

The aim of the study was to evaluate the risk of adverse effects and short-term results after 360 degrees selective laser trabeculoplasty (SLT) in glaucoma patients. The authors enrolled 64 eyes of 64 patients all who had poorly controlled primary...

SLT vs. topical treatment with prostaglandin analogues in the management of PACG

Selective laser trabeculoplasty (SLT) has been shown to be useful in the management of primary open angle glaucoma (POAG), but its use in primary angle closure (PAC) / primary angle closure glaucoma (PACG) has yet to be validated. Narayanaswamy et...

BELKIN Vision is pleased to announce FDA clearance for its glaucoma laser, the Eagle device

BELKIN Vision, an innovator in ophthalmic medical solutions, is pleased to announce that the US Food and Drug Administration (FDA) has granted 510(k) clearance for its glaucoma laser, the Eagle device.

SLT versus medication for OAG

This paper appraised existing randomised clinical trials (RCTs), which compared selective laser tabeculoplasty (SLT) with medical therapy for open-angle glaucoma (OAG), and performed a systematic review and meta-analysis. A total of 1229 patients in eight trials were included from PubMed,...

Carleton Optical Equipment Ltd is recruiting for its expanding Glaucoma team

Business Manager - We are looking for an ambitious and capable business manager responsible for the South of England.

The results of the last survey Aug22

The first question really highlights how we can become enshrined in the way we do things. I genuinely thought that everyone was using a cohesive viscoelastic for their cataract surgery. It was what I was taught, and I believe everyone...

Mono vs. multi-therapy in IOP control

This randomised control trial studied newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differences in initial intraocular pressure (IOP) reduction, target IOP levels reached and influence of untreated baseline IOP on IOP reduction. Patients newly diagnosed with manifest primary...

The National Treatment Centre-Highland

The National Treatment Centre-Highland opened its doors to patients in April 2023. At a cost of £48 million this represented a significant investment by the Scottish Government for the provision of modern eye care for the North of Scotland.

Evolving towards an interventional glaucoma mindset

Traditionally, a newly diagnosed glaucoma patient would be treated first with medical therapy. As the disease progressed or the initial intervention failed to adequately control intraocular pressure (IOP), clinicians would add more drops, selective laser trabeculoplasty (SLT), repeated SLT and...

Real-world experience and outcomes of SLT laser used as a first-line treatment in ocular hypertension patients in a United Kingdom National Health Service setting

The management of raised intraocular pressure (IOP) in the context of ocular hypertension (OHT) and primary open angle glaucoma (POAG) remains a major contributor to the workload of ophthalmology units across the UK. Treatment of these conditions has historically centred...
  • 1 (current)
  • 2
  • 3